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Abstract Available cholinergic drugs for treating
Alzheimer’s disease (AD) provide modest symptomatic
benefit. We hypothesized that co-administration of a pe-
ripheral anticholinergic to reduce dose-limiting adverse
effects (AEs) would enable the safe/tolerable use of
higher cholinesterase inhibitor doses and thus improve
their antidementia efficacy. A modified single-blind, as-
cending-dose, phase IIa study of donepezil plus
solifenacin (CPC-201) lasting 26 weeks was conducted
in 41 patients with probable AD of moderate severity.
Entry criteria included the use of donepezil at a dose of
10 mg/day during the preceding 3 months. The primary
outcome measure was the maximum tolerated dose
(MTD) of donepezil achieved (to protocol limit of
40 mg/day) when administered with the anticholinergic
solifenacin 15 mg/day. Secondary measures included as-
sessments of cognitive and global function, as well as of
AEs. The mean ± SD donepezil MTD increased to 38
± 0.74 mg/day (median 40 mg/day; p < 0.001); 88% of
the study population safely attained this dose at the end
of titration. Markedly reduced donepezil AE frequency,
especially gastrointestinal, allowed this dose increase.
There were no drug-related serious AEs or clinically
significant laboratory abnormalities. At 26 weeks,
Alzheimer ’s Disease Assessment Scale Cognitive
Component scores in the efficacy evaluable population
improved by 0.35 ± 0.85 points over baseline (p < 0.05),
an estimated 2.5 ± 0.84 points above 10 mg/day donepezil
and 5.4 ± 0.84 points above historic placebo (both
p < 0.05). Clinical Global Impression of Improvement
scores improved by 0.94 ± 0.20 to 3.1 ± 0.20 points
(p < 0.001). The findings suggest that limiting donepezil
AEs by co-administration of solifenacin allows the safe
administration of substantially higher cholinesterase in-
hibitors doses that may augment cognitive and global ben-
efits in patients with AD.
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Introduction
Background
Alzheimer’s disease (AD) is a progressive neurodegener-
ative disorder afflicting mainly the elderly [1]. Its cause
remains obscure and no treatment has yet been shown to
prevent onset or delay progression. Since clinical decline
is associated with a profound loss of cholinergic neurons
arising in the medial forebrain nuclei and an associated
reduction in acetylcholine-mediated neurotransmission
[2], drugs tending to normalize acetylcholine transmitter
levels, such as donepezil and related cholinesterase in-
hibitors (ChEIs), have for over 2 decades served as the
mainstay of symptomatic therapy [3]. Unfortunately,
none has proven more that modestly effective: even at
maximum tolerated doses (MTD), most patients with
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Alzheimer’s disease (AD) achieve only marginal clinical
benefits [4, 5].
A major factor contributing to this limited efficacy is the
marginal 25% to 30% inhibition of cortical ChE activity
achievedwith standard of care 5 or 10mg/day donepezil doses
[6, 7]. Higher dosing can achieve greater levels of ChE inhi-
bition [8], but dosing is limited in most patients by adverse
events (AEs), especially nausea, vomiting, and diarrhea [9].
Indeed, a 23-mg donepezil formulation, introduced in 2010
[10], gained relatively limited acceptance due mainly to gas-
trointestinal (GI) intolerance [11]. This is regrettable as both
animal model [12–14] and AD patient [10, 15–18] studies
suggest that, over a broad range, larger ChEI doses potentially
confer greater cognitive benefit.
The foregoing observations led us to hypothesize that
ChEI doses well above those currently approved, but ren-
dered safe and tolerable by the co-administration of a
second drug capable of inhibiting peripherally mediated
cholinergic AEs, might achieve substantially greater
symptomatic benefit and cognitive stabilization to those
suffering from AD. Initial support for this view derived
from multiple phase I studies showing that the addition of
a peripheral anticholinergic to donepezil or other ChEI
allows substantial increases in the MTD and associated
plasma concentrations [19]. This first-in-patient study
was thus designed to evaluate whether the MTD of a
ChEI could be substantially raised in patients with AD
by the co-administration of a peripheral anticholinergic,
and, secondarily, whether this additional agent might im-
prove cognitive function. The ChEI donepezil and the
antimuscarinic solifenacin were selected as an optimal
drug combination to test this hypothesis.
Donepezil hydrochloride is a selective, reversible ChEI
known to enhance cholinergic function both centrally and pe-
ripherally [20]. Initially approved for US marketing in 1996
for the treatment of AD, it has been sold generically since
2010 at daily doses of 5, 10, and, most recently, 23 mg.
Peak plasma concentrations of donepezil, which is 100% oral-
ly bioavailable, are achieved in approximately 3 h and the
biological half-life is about 70 h.
Solifenacin is a competitive cholinergic receptor antag-
onist, relatively selective for the M3 receptor subtype
[21]. It has been approved for the treatment of overactive
bladder disorder since 2004. At recommended doses of 5
and 10 mg/day, peak plasma levels of solifenacin are
attained within 3 to 8 h. Solifenacin is primarily metabo-
lized in liver by the cytochrome P450 enzyme CYP3A4
and excreted by the kidneys with an elimination half-life
of 45 to 68 h. It binds to hERG (human Ether-a-go-go-
Related Gene) channels in the heart and may prolong the
QT interval, although rarely to a clinically relevant degree
[22]. Multiple preclinical and clinical studies indicate that
solifenacin does not penetrate the blood–brain barrier
sufficiently to have a meaningful effect on cognition at
doses given in this trial [23].
Patients and Methods
Objectives and Study Design
The primary goal of this clinical trial was to determine the
MTD of donepezil that could be safely given to patients with
moderate AD when administered in combination with
solifenacin as CPC-201. AS all those admitted to this study
had been chronically treated with stable doses of donepezil for
at least 3 months at their putative MTD of 10 mg/day, the
donepezil dose increment enabled by the addition of a periph-
eral anticholinergic could be estimated. Secondarily, this study
explored the potential effects of higher-dose donepezil to pro-
vide signals suggesting additional cognitive and global
benefit.
In pursuit of this goal, a modified placebo-controlled, dose-
escalation, crossover study was conducted at 7 sites in the
USA from 19 August 2014 to 3 March 2016. The outpatient
study used a modified single-blind design: patients and their
caregivers, as well as cognitive measure raters and other study
personnel, remained masked to treatment status, with the ex-
ception of the coordinator and a physician at each site who
controlled dosing. Both the protocol and informed consent
were approved by the independent ethics committee/
institutional review board for each independent site and
conformed to the principles of the World Medical
Association Declaration of Helsinki and all local regulations.
The study design was also reviewed and deemed appropriate
by the US Food and Drug Administration (Investigational
New Drug Application 114776).
Study Population
Patients eligible for this trial ranged in age from 50 to 89 years
and had a diagnosis of probable dementia of the Alzheimer’s
type, as defined in the American Psychiatric Association’s
Diagnostic and Statistical Manual of Mental Disorders [24],
and based on National Institute of Neurological and
Communicative Diseases and Stroke, Alzheimer’s Disease
and Related Disorders Association criteria [25]; had a Mini-
Mental State Examination (MMSE) score [26] of 10 to 20
(moderate impairment); were ambulatory and free of anymed-
ical condition that would adversely affect the safety or infor-
mative value of this study; and had clinical laboratory values
within normal limits, or, if abnormal, considered by the inves-
tigator and sponsor to be not clinically significant.
All participants had been treated with donepezil 10 mg/day
for at least 12 weeks prior to study entry. Patients taking
memantine, at stable doses of either 20 mg/day immediate
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release or 28 mg/day extended release for at least 8 weeks
before screening, were allowed to continue at that dose
throughout the trial. All patients were required to have care-
givers who either lived with or had daily contact with the
patient and were not considered by the investigator to be cog-
nitively impaired to a degree compromising their evaluations
regarding safety/tolerability and global functioning.
Patients were excluded if they had a history or presence of
seizures; myasthenia gravis; peptic ulcer; GI obstructive disor-
der or reduced GI motility; narrow-angle glaucoma; urinary
retention; unexplained syncope; family history of sudden
death; myocardial infarction or hospitalization for congestive
heart failure within the prior 6 months; history of implanted
cardiac pacemaker or implantable cardiac defibrillator; electro-
cardiogram (ECG) findings of prolongedQT interval, complete
left bundle branch block, ventricular pacing, second-degree or
third-degree atrioventricular block, atrial fibrillation or atrial
flutter, heart rate <45 or >100 beats per min; PR > 220 ms, or
QTcF >450 ms in males or >470 ms in females; patients treated
with the following medications within 8 weeks of screening:
AD treatments (other than donepezil and memantine), periph-
erally acting anticholinergics (e.g., drugs for the treatment of
overactive bladder disorder), psychoactive medications (in-
cluding antipsychotics, antidepressants, anxiolytics, or sedative
hypnotics) having significant anticholinergic effects, and/or be-
lieved to affect alertness or cognitive function.
Prior to initiating study procedures, investigators obtained
written informed consent from each patient, if possible, or
from the patient’s legal authorized representative. If a patient
was unable to provide written consent, he or she was required
to provide verbal assent to participate in the study.
Additionally, the caregiver or legal authorized representative
was required separately to provide written informed consent
for his or her own participation in the study.
Study Drug Administration
The CPC-201 trial consisted of 4 phases (baseline, solifenacin
titration, donepezil titration, and MTD maintenance), nomi-
nally lasting 2 days, 2 weeks, 12 weeks, and 12 weeks, re-
spectively, for a total of approximately 26 weeks. Study med-
ications were taken together, once daily in the morning
throughout the trial. The blind was maintained by means of
a double-dummy system. At every clinic visit patients re-
ceived daily packs of 6 tablets; 2 similarly appearing tablets
contained either active or placebo solifenacin, and 4 similarly
appearing tablets contained either active or placebo donepezil.
Upon study admission, patients switched from their ongo-
ing 10 mg/day dose of donepezil to the constant 6 tablet/day
regimen. Initially, 1 donepezil tablet contained 10 mg, while
all other tablets were inactive. Subsequently, in accordance
with the protocol titration schedule, placebo solifenacin was
replaced by active solifenacin at a dose of 10 mg/day and
increased after 1 week to 15 mg/day. Donepezil was then
increased by weekly 5-mg increments to 25 mg and thereafter
at every-other-week intervals to each patient’s first intolerable
dose or the protocol maximum of 40 mg/day. Patients
attaining their first intolerable dose were immediately reduced
to their previous MTD. Upon titration phase completion, all
patients entered a MTD maintenance phase lasting 3 months.
Study drug dosing was always permissive, consistent with
patient needs and investigator discretion. Compliance, evalu-
ated by counting unused tablets from each patient at every
clinic visit, as well as by periodic measurements of peak and
trough plasma levels of both study medications, was >98%.
At the end of the study, all patients were given, at the inves-
tigators’ discretion, the option of entering a 6-month open-
label extension or exiting after returning to their previous
treatment regimen and receiving a final safety check.
Safety and Efficacy Assessments
The primary outcome measure for this exploratory phase IIa
study was the difference in the highest stably tolerated dose of
donepezil when administered alone and when given together
with solifenacin (15 mg/day). Secondary measures included
safety–tolerability and initial efficacy assessments, conducted
at regular intervals, as well as by standard laboratory tests.
Patients returned to the clinic for evaluation at each dose ad-
justment or else at weekly intervals during dose titration (up to
the week-14 visit) and at monthly intervals duringMTDmain-
tenance (at the week 18, 22, and 26 visits). Regular telephone
contact between site staff and patient/caregivers maintained
interim surveillance.
Safety assessments included clinical laboratory testing (he-
matology, biochemistry, and urinalysis panels analyzed by a
central laboratory that met regulatory certification require-
ments), 12-lead ECG read centrally by a cardiologist with
advanced training, and physical and neurologic examinations,
including vital sign measurements, at all clinic visits. Blood
pressure and heart rate were measured in the supine position.
Temperature, respiratory rate, and weight were also deter-
mined at all clinic visits. Height was recorded at screening.
In addition, possible deleterious effects of solifenacin on cog-
nitive function were assessed by means of the Alzheimer’s
Disease Assessment Scale Cognitive Component (ADAS-
cog) scale at baseline and usually 2 weeks later when a dose
of 15 mg/day had been achieved, both time points where the
donepezil dose remained at 10 mg/day.
Treatment-emergent adverse event (TEAE) listings derived
from spontaneous reports frompatients and/or caregivers, aswell
as open-ended questioning, throughout the study. The severity of
each TEAE (mild, moderate, or severe) and its relation to study
medications (unrelated, possibly, probably, or definitely related)
were determined by the investigators and reviewed by the Data
Safety Monitoring Board (DSMB) and the sponsor.
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Secondary outcome measures also included the 11-item
ADAS-cog to evaluate safety, as well as a potential indicator
of efficacy after completion of donepezil titration (at the week-
12 visit) and again after 1, 2, and 3 months of MTD mainte-
nance. In addition, the Clinical Global Impression of
Improvement (CGI-I) scale was performed at study comple-
tion during the week-26 visit.
The ADAS-cog is an 11-item instrument commonly used
in AD trials to assess cognitive function [27]. Disturbances in
such core symptoms of AD as memory, language, praxis, and
attention are evaluated. Total scores range from 0 (most im-
paired) to 70 (least impaired). Blinded, trained raters after
fulfilling qualification standards and demonstrating satisfacto-
ry performance on tests of rating proficiency performed the
ADAS-cog assessments. With few exceptions, patients were
evaluated by the same rater throughout the trial.
The CGI-I is a semistructured tool that provides an overall
assessment of how much a patient's illness has changed,
whether or not entirely due to study medications, relative to
their baseline state at the beginning of the intervention [28].
Patients were rated once at the end of the study independently
by both the investigator and the caregiver on a 7-point scale
(1 = marked improvement; 2 = moderate improvement;
3=minimal improvement; 4 = no change; 5 =minimal wors-
ening; 6 = moderate worsening; 7 = marked worsening).
Raters were asked to rate overall change, taking into account
all available information, compared with the patients’ condi-
tion at baseline [29]. For both the ADAS-cog and CGI-I mea-
sures, a negative change indicates improvement.
The MMSE is a 30-item test of cognitive function, with
total scores ranging from 0 (most impaired) to 30 (least im-
paired) [26]. It was employed as a screening tool to determine
admission eligibility. The same rater generally administered
the ADAS-cog and then the MMSE.
The pharmacokinetics of donepezil alone (at baseline) and
with solifenacin (at all subsequent times) were assessed at
both trough (15 min before daily drug administration) and
nominal peak drug levels (4 h later) at time points including
baseline, end of solifenacin titration, end of donepezil titra-
tion, end of each month of MTD donepezil maintenance, and
at study conclusion.
Statistical Analysis
A sample size of 34 evaluable patients was planned to provide
an overall power of ≥80% to observe a significant difference
in the putative MTD of donepezil, prior to study entry when
given alone at 10 mg/day and at the end of donepezil titration
when given with solifenacin 15 mg/day as CPC-20.
Safety and tolerability were analyzed in the safety popula-
tion (all those who received at least 1 dose of study medica-
tion). Efficacy analyses were performed on both the intention-
to-treat (ITT) and the efficacy evaluable populations. The ITT
was defined as all randomized patients who had at least 1
postbaseline assessment. The efficacy evaluable population
was defined as all those who received study drugs, attended
all study visits, and participated in all study procedures lead-
ing to the determinations. The primary efficacy endpoint
(change in donepezil dose) was analyzed in the ITT popula-
tion. The secondary efficacy measures (cognitive and global
change) were assessed in the efficacy evaluable population.
Post-hoc analyses of the impact of patient age, sex, baseline
symptom severity, and concomitant medications on the re-
sponse to treatment were conducted.
Since this initial phase II trial did not include a placebo
arm, adjustment of ADAS-cog differences from baseline to
changes from 10 mg donepezil and from placebo was based
on an independently performedmeta-analysis of the published
literature [30]. Prior to breaking the blind, selection of ran-
domized controlled trials for inclusion in this analysis relied
on quality (internal validity) of search strategies and selection
criteria developed by the Cochrane Collaboration [31] follow-
ed by comparability criteria devised a priori for this study,
including such factors as disease severity, donepezil dose,
treatment duration, and outcome measures [3, 32–37].
Similarly, the slope of cognitive decline during placebo or
10 mg/day donepezil treatment was estimated to be 0.0119
ADAS-cog points per day. Finally, a mean effect of 10 mg
donepezil of 2.9 ADAS-cog points above placebo also derived
from meta-analyses of data from multiple trials [31, 38–40].
The present study, the first phase II evaluation of CPC-201,
was intended to be hypothesis raising rather than hypothesis
testing; it was thus not powered to yield reliably statistically
significant conclusions with respect to neurobehavioral efficacy.
The data were analyzed by means of descriptive statistics (in-
cluding means and SEs to reveal possible trends that might help
guide the design of future, more definitive, clinical trials). An
analysis of covariance model with terms for baseline score and
treatment was used as the primary model for testing treatment
effects on ADAS-cog scores ± SEM values used to compare
treatment groups. For the categorical endpoint, CGI-I score at
the 26-week visit a nonparametric analysis of covariancemethod
combined with a Cochran–Mantel–Haenszel test component
was used. All statistical tests, 2-sided at a significance level of
0.05, were conducted using SAS version 8.0 or higher [41] by
Amarex LLC [30]. An independent safety monitoring board
(DSMB) determined that the study could proceed as planned.
Results
Patient Baseline Characteristics and Disposition
Baseline demographic and clinical characteristics of the 41
patients comprising the ITT/safety population are presented
in Table 1. Eligible patients ranged in age from 57 to 88 years.
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Most were white (93%) women (54%). MMSE scores fell in
the moderate range of 10 to 20; 61% continued to receive their
established dose of memantine throughout the trial. Other fre-
quent concomitant medication classes used during the study
included lipid-lowering agents (58%), antidepressants (54%),
and antihypertensives (44%).
Figure 1 summarizes the disposition of the ITT population.
Eleven premature withdrawals occurred during this trial: 8
patients dropped out during initial solifenacin or donepezil
titration, and 3 during stable dose maintenance. The reasons
were: nonconformance with inclusion/exclusion criteria (4 pa-
tients), consent withdrawal (3 patients), bilateral plantar der-
matitis unrelated to study drugs (1 patients), bradycardia un-
related to study drugs that persisted unchanged from baseline
(2 patients), and atrial fibrillation unrelated to study drugs
discovered at an in-clinic visit during donepezil upward dose
titration (1 patient). No withdrawal was attributed by the in-
vestigator or the DSMB to a drug-related AE.
Solifenacin Administration
Solifenacin was given orally at a daily dose of 10 mg for
1 week and then increased to 15 mg for the remainder of the
trial. The peripheral anticholinergic produced no untoward
clinical or laboratory effects in the 41-patient safety popula-
tion. Specifically, there were no symptoms of neuropsycho-
logical dysfunction reported, and cognition measured by the
ADAS-cog after 2 weeks of solifenacin treatment did not
change [mean ± SEM of 26.9 ± 1.25 at baseline (donepezil
10 mg/day only) vs 26.9 ± 1.28 after treatment (donepezil
10 mg/day plus solifenacin 15 mg/day) for a difference of
0.012 ± 0.76 (n = 26; p = nonsignificant)]. At no later time
during the study were centrally mediated untoward effects of
solifenacin detected or a need for a downward dose adjust-
ment recognized.
Table 1 Summary of baseline demographics of Alzheimer’s disease
patients entering CPC-201 trial
Characteristic n (%)
Sex
Male 19 (46.3)
Female 22 (53.7)
Mean ± SD age (y) 73.1 (8.2)
Age range (y) 57–88
Race
White 38 (92.7)
Black/African American 3 (7.3)
Asian 0 (0)
Mean ± SD weight (kg) 76.4 ± 18.0
Weight range (kg) 40–117
Mean ± SD (median) duration of Alzheimer’s disease (y) 3.4 ± 2.7 (3.0)
Range 0.5–11
Mean± SD duration of donepezil treatment prior to study
entry (d)
833.8 ± 718.3
Range 70–2680
Concomitant memantine
Yes 25 (61.0)
No 16 (39.0)
Mean ± SD baseline ADAS-cog 28.5 ± 8.3
Range 15–46
Mean ± SD baseline MMSE 16.5 ± 3.10
Range 11–20
Data are n (%) unless otherwise indicated
ADAS-cog = Alzheimer’s Disease Assessment Scale Cognitive
Component; MMSE = Mini-Mental State Examination
Discontinued during solifenacin titration (n=3)*
• No longer met Inclusion/Exclusion criteria‡ (n=2)
• Bradycardia that persisted unchanged from 
baseline (n=1)
Discontinued during CPC-201 dose titration (n=5)*
• Consent withdrawn (n=1)
• Adverse event (n=1) unrelated to CPC-201
• ‡No longer met Inclusion/Exclusion criteria (n=2)
• Atrial fibrillation (n=1) unrelated to CPC-201
Discontinued during dose maintenance (n=3)
• Consent withdrawn (n=2)
• Bradycardia that persisted unchanged from 
baseline (n=1)
Enrolled (n=41)
Completed solifenacin
dose titration (n=38)
Completed donepezil
dose titration (n=33)
Completed dose
maintenance (n=30)
Fig. 1 Disposition of patients
with moderate Alzheimer’s
disease enrolled in the study of
CPC-201. No patient
discontinued owing to possible or
probable drug-related adverse
events or to a perceived lack of
efficacy. *Of 8 patients who
discontinued during titration, 3
occurred during solifenacin
titration and 5 during donepezil
titration ‡Post-enrollment, 4
patients were excluded as
ineligible pursuant to protocol
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Primary Endpoint
Maximum Tolerated Dose of Donepezil
Patients admitted to this study had been treated with standard
donepezil (10 mg/day) for at least 3 months. Clinically, all
were considered by their investigator to be responding satis-
factorily. Once a solifenacin dose of 15 mg/day had been
achieved, the amount of donepezil was gradually increased
to the protocol maximum of 40 mg/day or to each patient’s
first intolerable dose (then reduced to the next lower dose).
Donepezil titration took an average of 9.6 ± 0.62 weeks,
prolonged by efforts to accommodate to such matters such
as scheduling convenience, as well as drug tolerability.
All patients completing donepezil dose titration attained the
primary goal of safely and tolerably increasing their MTD of
this ChEI when co-administered with the anticholinergic
solifenacin (Fig. 2). Indeed, 100% reached 25 mg/day and
88% of the 33 evaluable patients tolerated the maximum pro-
tocol allowable dose of 40 mg/day. The mean donepezil dose
in this group was 38 ± 0.74 mg/day (p < 0.0001) and the me-
dian dose was 40 mg/day or 4-fold above that tolerated prior
to admission. This dose increment was stably maintained
throughout the final 3 months of the study. Three of the 4
(12%) patients who failed to attain a donepezil MTD of at
least 40 mg/day evidenced GI intolerance and plasma
donepezil levels approximating those occurring with a
40 mg/day dose in this total study population.
Secondary Endpoints
This phase IIa study mainly conducted to determine the size of
its primary efficacy outcome measure. It was neither designed
nor powered to provide statistical assessments of secondary
measures of safety or efficacy, but rather to suggest data trends
suitable for possible future evaluation.
Safety—Tolerability
TEAEs, whether or not considered CPC-201 related, that oc-
curred in more than 1 individual are presented in Table 2.
Most emerged during the period of donepezil dose titration
(71% of patients), less during donepezil MTD maintenance
(58%), and least during the solifenacin titration phase (12%).
Themost frequently reported TEAEs deemed probably related
to CPC-201 treatment involved the GI system. These occurred
mainly during donepezil dose titration and included diarrhea
(6 of 38 patients; 16%), nausea (4 of 38; 11%), and vomiting
(4 of 38; 11%). In contrast, during CPC-201 MTD mainte-
nance, only 2 patients (6%) developed diarrhea, and none had
nausea or vomiting. Regarding solifenacin, just 1 individual
(3%) was considered to have a TEAE (constipation) possibly
or probably related to the anticholinergic during donepezil
MTD maintenance.
Most TEAEs, drug related or not, were mild (68% of pa-
tients) or moderate (54%) in severity. During this trial, severe
AEs occurred in 7 (17%) patients. All were unique and none
was considered related to treatment. Serious TEAEs occurred
in 8 patients (20%); all were considered unrelated to treatment.
Only 1 patient prematurely withdrew from the study due to a
TEAE: bilateral plantar dermatitis judged unrelated to CPC-
201 treatment. The death of 1 patient (from pneumonia
2 weeks after stopping study medications) was also not con-
sidered related to the treatment.
During the entirety of this trial, there were no clinically
meaningful changes in clinical, vital signs (blood pressure,
heart rate, or heart rhythm), or standard laboratory assess-
ments. Although no significant change in mean body weight
occurred, decreased weight as an AE was reported in 1 patient
(2%). Compared with baseline, 2 patients (5%) had a weight
decrease of ≥7% at the end of the study. QTcF intervals, read
centrally from routine paper ECGs obtained 4 h postdrug in-
take and at each dose increase and at monthly intervals during
maintenance, averaged (mean ± SD) 421 ± 22.2 ms at baseline
(10 mg/day donepezil monotherapy; n = 41), 436 ± 23.7 ms at
solifenacin steady state (n = 35), and 436 ± 22.6 ms at the end
of the 12-week maintenance (n = 30). There was no correla-
tion between QTcF change and plasma donepezil or
solifenacin concentrations and all QTcF increments remained
<60 ms from baseline, except for 1 individual who had brief,
transient increases to 78 ms.
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Fig. 2 Maximum tolerable dose (MTD) of donepezil during
preadmission monotherapy (10 mg/day) and MTD or maximum
allowed donepezil dose (MAD= 40 mg/day) at completion of donepezil
plus solifenacin (CPC-201) dose titration. Histogram compares donepezil
doses in 33 patients with moderate AD, as determined first by history
(from investigators or referring physicians) and again at completion of
donepezil (plus solifenacin 15 mg/day) dose titration. A maximum
donepezil dose of 25 mg/day was tolerated by 100% and of 40 mg/day
by 88% of CPC-201 treated patients (*p < 0.001 for difference in
donepezil dose administered as monothrerapy at baseline and co-
administered with solifenacin as CPC-201 at the end of dose titration)
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Cognitive Function
ADAS-cog scores showed a positive treatment effect that
remained above baseline throughout the course of this 26-
week study (Fig. 3). Cognitive improvement peaked following
completion of donepezil titration to MTD at the 18-week visit.
Subsequently, mean ADAS-cog scores declined at an ostensi-
bly linear rate that appeared to parallel the historic slope of
10 mg/day donepezil monotherapy, estimated as described in
the BPatients and Methods^ section. During the stable-dose
maintenance period, cognitive benefit from CPC-201 averaged
about 2.5 points above that estimated for standard 10 mg/day
donepezil (n = 23, p < 0.05; Table 3). Further adjustment of this
ADAS-cog benefit for that already received from the 10 mg/
day dose of donepezil all patients were receiving at study entry
(based on the previously described meta-analysis) suggested
that CPC-201 produced a mean improvement of 5.4 ± 0.84
points over placebo at trial completion.
Responder analysis of the completed trial results showed
that 14 (61%) of the efficacy evaluable population hadADAS-
cog change scores of 0 to −7 and were thus regarded as CPC-
201 responders, while 9 (39%) had change scores <0 and were
considered nonresponders. At the end of the 26-week trial,
ADAS-cog increments for responders averaged −2.9 ± 0.77
points above baseline and −7.9 ± 0.77 points above placebo
Table 2 Treatment emergent
adverse events (TEAEs)
occurring in more than 1 patient,
by treatment period, and preferred
term, by descending order of
frequency during donepezil
titration period
TEAE preferred term Number (%) of patients
Solifenacin upward
dose titration
Donepezil upward
dose titration
Donepezil dose
maintenance
(n = 41) (n = 38) (n = 33)
n (%) n (%) n (%)
Number of patients with any TEAE 5 (12.2) 27 (71.1) 19 (57.6)
Diarrhea 6 (15.8) 2 (6.1)
Nausea 4 (10.5)
Vomiting 4 (10.5)
Abdominal discomfort 3 (7.9) 1 (3.0)
Decreased appetite 3 (7.9)
Dizziness 3 (7.9) 2 (6.1)
Constipation 1 (2.4) 2 (5.3) 1 (3.0)
Agitation 2 (5.3) 1 (3.0)
Somnolence 2 (5.3)
Syncope 2 (5.3) 1 (3.0)
Tremor 2 (5.3) 1 (3.0)
Pyrexia 2 (5.3)
Fall 1 (2.4) 1 (2.6) 4 (12.1)
Abdominal pain 1 (2.4) 1 (2.6) 1 (3.0)
Bradycardia 1 (2.4) - - 1 (3.0)
Electrocardiogram QT prolonged 1 (2.6) 1 (3.0)
Arthralgia 2 (6.1)
Paresthesia 1 (2.6) 1 (3.0)
Irritability 1 (2.6) 1 (3.0)
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Fig. 3 Time course of Alzheimer’s Disease Assessment Scale Cognitive
Component (ADAS-cog) score (mean ± SEM) response to donepezil
40 mg/day plus solifenacin 15 mg/day (CPC-201) in 23–26 efficacy
evaluable patients with moderate Alzheimer’s disease during the 26-
week study and to donepezil 10 mg/day monotherapy as derived from
meta-analysis of comparable randomized controlled trials as described in
text. Donepezil dose titration until week 12 was followed by stable dose
maintenance for 14 additional weeks. Negative ADAS-cog values
indicate improvement *p = 0.051 for difference from donepezil
monotherapy
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(both p < 0.05 for n =14). Indeed, all 14 of the responding
individuals had estimated ADAS-cog benefit above placebo
of at least 4 points.
Domain analysis of the ADAS-cog results at trial conclusion
revealed that Memory [sum of items 4 (Word recall), 6
(Orientation), and 10 (Word recognition)] responded
substantially better than Language [Sum of Item 1 (spoken
language ability), Item 2 (Comprehension), Item 3 (Word finding
difficulty), Item 5 (Naming objects and fingers), and Item 11
(Remembering test instructions)] or Praxis [Sum of Items 7
(commands), 8 (ideational praxis), and 9 (constructional praxis)].
Moreover, mean baseline scores for the 3 items comprising the
memory domain averaged substantially worse (7.01) than those
for the remaining 8 ADAS-cog items (0.85). The severity of
memory dysfunction thus might serve as a possible predictor of
the response to strong cholinomimetic stimulation.
Global Function
The CGI-I results indicated substantial global improvement at
the end of this 26-week trial (Table 4). Scores obtained
independently from investigators and caregivers from all those
in the efficacy evaluable population receiving this test did not
differ significantly but averaged somewhat higher from care-
giver group. Independently and in combination CGI scores
revealed significant benefit. At study conclusion, investigator,
caregiver and combined CGI score all improved significantly
from the pretreatment baseline (p < 0.001), the latter by an
average of 0.94 ± 0.20 points (n = 16 in efficacy evaluable
population). Responder analysis indicated that all but 1 indi-
vidual in this group were considered to have improved with
CPC-201 therapy (Fig. 4).
Predictors of Treatment Response
None of the demographic or other patient characteristics mea-
sured at baseline in this study were found on post hoc analysis
to relate significantly to changes in overall cognitive or global
function. More specifically, neither age, sex, baseline demen-
tia severity, nor concomitant memantine appeared to affect the
Table 3 Effect of CPC-201
treatment on cognitive function in
patients with moderate
Alzheimer’s disease measured by
Alzheimer’s Disease Assessment
Scale Cognitive Component
(ADAS-cog) changes from
baseline and estimated from
10 mg donepezil and from
placebo response
Mean treatment
weeks
Median donepezil
dose (mg/kg)
Number
of patients
ADAS-cog difference from:
Baseline* Aricept 10 mg† Placebo†
14 40 26 −0.55 ± 0.92 −1.6 ± 0.88 −4.5 ± 0.88‡
18 40 25 −1.1 ± 1.1 −2.5 ± 1.1‡ −5.4 ± 1.1‡
22 40 24 −0.61 ± 1.1 −2.4 ± 1.1‡ −5.3 ± 1.1‡
26 40 23 −0.35 ± 0.85 −2.5 ± 0.84‡ −5.4 ± 0.84‡
ADAS-cog scores from the evaluable population are the means ± SEM, with negative scores indicating
improvement
*Differences from baseline measured during stable maximum tolerated dose maintenance at the times after CPC-
201 treatment initiation specified
†Differences from values for 10 mg/day donepezil and placebo derive from meta-analyses of results from
comparable randomized controlled trials meeting Cochrane Collaboration quality guidelines, as described in
the text
‡ p < 0.05
Table 4 Effect of 26 weeks of CPC-201 treatment on global function in
patients with moderate Alzheimer’s disease as measured by the Clinical
Global Impression of Improvement (CGI-I) scale
Rater CGI-I score
(mean ± SEM)
Change from baseline
(mean ± SEM)
Investigator 3.3 ± 0.19 −0.75 ± 0.19*
Caregiver 2.9 ± 0.27 −1.1 ± 0.27*
Combined 3.1 ± 0.20 −0.94 ± 0.20*
Values are from 16 evaluable patients at the completion of 26 weeks
treatment with CPC-201 containing a median donepezil dose of 40 mg/
day. Baseline score is 4 (no change) on a 7-point scale ranging from 1
(marked improvement) to 7 (marked worsening). Negative changes indi-
cate improvement
*p < 0.01
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Fig. 4 Histogram of global response to donepezil (median dose of
40 mg/day) plus solifenacin (15 mg/day) administered as CPC-201 at
end of 26-week study in 11 efficacy evaluable patients with moderate
Alzheimer’s disease. The Clinical Global Impression of Improvement
(CGI-I) was scored on a 7-point scale by both investigators and caregivers
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CPC-201 response as measured by the ADAS-cog or CGI-I in
this small patient sample. However, patients continuing to
receive their previous dose of memantine tended to have a
larger ADAS-cog response above baseline than those not re-
ceiving memantine, although this difference did not attain
statistical significance (p > 0.05).
Pharmacokinetics
Mean peak plasma donepezil concentrations increased linear-
ly over the range of ChEI doses studied (Fig. 5). Donepezil
levels averaged 57 ± 3.4 ng/ml (n = 41) at baseline (10 mg/day
donepezil monotherapy) and 67 ± 4.0 ng/ml after the addition
of 15 mg/day solifenacin (n = 36; p > 0.05 for difference from
donepezil alone). Following titration to a median dose of
40 mg/day (in combination with solifenacin), mean donepezil
concentrations increased to 258 ± 14.2 ng/ml (n = 32), ranging
from 104 to 420 ng/ml. This 4.5-fold increase in plasma
donepezil remained essentially stable throughout the dose
maintenance phase of the study. Solifenacin levels averaged
64 ± 4.6 ng/ml (n = 37) at the end of the 2-week titration to
15mg/day and 78 ± 7.2 ng/ml (range 24–194 ng/ml; n = 29) at
study conclusion. No significant drug–drug interactions or
drug–efficacy correlations emerged from examination of this
relatively limited data set.
Discussion
This small, first-in-patient clinical trial found that solifenacin
co-administration enabled the dose of donepezil to be safely
increased to 40 mg/day in 88% of patients with moderate AD.
Treatment with high-dose CPC-201, which combines the
ChEI with the peripheral anticholinergic, resulted in a more
than 4-fold increment in circulating donepezil concentrations
and thus brain exposure to the therapeutic agent. Solifenacin
administration, in amounts that failed to produce any
detrimental effects on cognition, allowed this dose increase
by diminishing all TEAEs of donepezil, especially those in-
volving the GI system. At trial conclusion, measures of both
cognitive and global function suggested significant improve-
ment with high-dose donepezil-containing CPC-201 over
standard 10 mg donepezil in patients with moderate AD.
The present results with solifenacin co-administration sup-
port the hypothesis that the dose-limiting AEs of donepezil-
like ChEIs reflect peripheral, not central, muscarinic receptor
stimulation [19]. They are also consistent with the view that
profound under dosage contributes to themeager antidementia
efficacy of currently approved donepezil treatments [7, 10,
19]. Finally, the findings of this study add strength to the view
that higher ChEI doses, within the range evaluated here, may
bring greater cognitive benefit to patients with AD [3, 10–18].
All 33 efficacy evaluable patients completing the drug ti-
tration phase tolerated CPC-201 containing at least 25 mg/day
of donepezil (thus exceeding the highest currently approved
donepezil dose) and nearly all (88%) reached the per-protocol
maximal allowable dose of 40 mg/day. Plasma donepezil con-
centrations in the 4 (12%) individuals who did not attain
MTDs of at least 40 mg/day averaged well above those ex-
pected from the dose they received. An ongoing extension
study suggests that donepezil doses up to at least 60 mg/day
(combined with solifenacin 15 or 20 mg/day) are well tolerat-
ed by most patients with AD. By contrast, repeated doses of
donepezil monotherapy in the 45 to 180 mg/day range (plas-
ma concentrations extending from 55 to 546 ng/ml) are report-
ed only in the toxicology literature, usually in association with
unintentional overdose and severe adverse effects [42, 43].
Pharmacokinetic results, notwithstanding relatively wide scat-
ter, confirm that higher donepezil doses bring proportionally
greater plasma levels.
No medically significant safety issues emerged during the
course of this trial. High donepezil doses failed to slow signif-
icantly heart rate or reduce blood pressure. The well-known
tendency of solifenacin to prolong the QT interval was ob-
served [22], but when co-administered with 40 mg/day
donepezil this effect failed to worsen to a clinically significant
degree. Similarly, no deleterious cognitive consequences
attended solifenacin administration.
AE frequency during the high-dose donepezil containing
CPC-201 maintenance phase decreased by about 80% of that
observed in comparable randomized control trials of 10 mg/
day donepezil [44]. High-dose CPC-201 appeared especially
superior to currently available donepezil dosage forms in re-
lation to GI tolerance. Indeed, the most frequent AEs during
CPC-201 maintenance were injuries due to accidental falls in
4 individuals, 3 of whom had a history of frequent falls. The
dearth of solifenacin-related AEs in this study suggests that
the cholinomimetic and anticholinergic components of CPC-
201 tend to mutually antagonize the peripherally mediated
effects of the other.
Fig. 5 Peak plasma donepezil (Cmax) concentrations at all doses
administered during ascending CPC-201 dose titration to 41 patients
with moderate Alzheimer’s disease. *No solifenacin co-administration;
all other donepezil doses given with 15 mg/day solifenacin
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This exploratory trial was neither designed nor powered to
detect reliably improvement in secondary behavioral out-
comes measures such as the ADAS-cog or CGI-I. These
scales were primarily intended to detect possible centrally
mediated adverse effects of high-dose solifenacin.
Nevertheless, ADAS-cog scores remained consistently above
baseline throughout the administration of high-dose CPC-201.
At study end, both the ADAS cog and CGI-I results were
significantly improved compared with their baseline values
(p < 0.05). Indeed, the estimated 5.4-point ADAS-cog incre-
ment over placebo, as well as the 0.94-point CGI-I benefit
above baseline, appear to exceed that reported for any current-
ly approved AD medication [10, 31, 38–40]. For the 61% of
the efficacy evaluable patients considered to be CPC-201 re-
sponders, all enjoyed a clinically meaningful cognitive im-
provement of at least 4 ADAS-cog points.
Some animal model studies suggest that the response to
ChEIs such as donepezil assumes an inverted U-shaped dose
response at high doses [45]. While true at excessive (barely
subtoxic) amounts [46], the present results appear to provide
no support for this view in patients with AD receiving up to
40 mg/day of donepezil. Indeed, comparison of 40 mg/day
donepezil-containing CPC-201 results with those for 5, 10,
and 23 mg/day suggest an essentially dose-proportional in-
crease in the range studied [10, 31]. The ADAS-cog response
to the 40 mg/day donepezil-containing CPC-201 appeared
nearly double (occurring with the standard 10 mg/day
donepezil formulation) [31, 38–40]. These preliminary obser-
vations thus lend support to the view that donepezil doses
above those currently approved may actually confer greater
antidementia efficacy.
A diagnosis of AD was required for inclusion in this trial.
However, a possibly better target for cholinomimetic interven-
tions like CPC-201 might be those suffering from a
hypocholinergic dementia, whether or not they satisfy AD
diagnostic criteria. Unfortunately, as yet, there is no clinical
means to identify reliably those with a cognitively significant
loss of cerebral cholinergic transmission. In the present study,
individuals with the greatest deficit in ADAS-cog items mak-
ing up the memory domain tended to be those having the
greatest memory item and overall cognitive response to
CPC-201 [47]. Going forward, it may be important to find
dependable ways to identify optimal ChEI responders to better
focus therapeutic interventions and improve the cost-
effectiveness of symptomatic antidementia therapies [48].
Both the degree of improvement in CGI-I scores and the
proportion of patients improving appeared larger than reported
from earlier trials of 10 mg/day donepezil using the similar
CIBIC+ scale [32, 33, 35]. Indeed, the 23-mg donepezil study
in patients with severe AD reported no apparent global im-
provement between 10 and 23 mg doses [10]. In contrast, all
but a single individual in the present trial were judged un-
changed or improved on the CGI-I scale. Conceivably, there
may be neurobehavioral domains benefitted by CPC-201 not
captured on the ADAS-cog, since, as commonly reported,
only about 60% of patients responded to this scale [49].
Assuming only those having a cholinergic deficit that substan-
tially contributes to their dementia will significantly benefit
from cholinomimetic therapy, the present results could sug-
gest that brain hypocholinergia contributes to the memory loss
occurring in almost two-thirds of patients diagnosed with mid-
stage AD and especially to the various associated disturbances
(as assessed by broader CGI type psychometric measures) that
manifest in a considerably larger proportion of these
individuals.
Conclusions regarding a potentially improved efficacy of
high-dose donepezil in CPC-201 in those with mid-stage AD
based on the findings of the present exploratory study must be
regarded with caution. Nevertheless, the results encourage
further evaluation of this possibility in a fully powered, ran-
domized, and controlled clinical trial.
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